View point. Bisphosphonates, osteoporosis and cardiovascular diseases

Kartikey K.¹ , Singh G.¹ , Singh R.B. ¹ , Al-Bawareed O.A. ² , Mojto V.³ , Chibisov S. ⁴ , Kharlitskaya E. ⁵ , Abramova M. ⁶ , Blagonravov M. ⁷

World Heart Journal

3

Английский

229-234

Опубликовано

Внешняя ссылка

10

2018

• ¹ Halberg Hospital and research Institute, Moradabad, India
• ² Department of Normal Physiology, People’s Friendship University of Russia, Moscow, Russian Federation
• ³ Faculty of Medicine, Comenius University, Bratislava, Slovakia
• ⁴ Department of Pathology and Pathophysiology, People’s Friendship University of Russia, Moscow, Russian Federation
• ⁵ Faculty of Veterinary Sciences, People’s Friendship University of Russia, Moscow, Russian Federation
• ⁶ Department of Anatomy, People’s Friendship University of Russia, Moscow, Russian Federation
• ⁷ Department of Pathophysiology, RUDN, Moscow, Russian Federation

alendronic acid; bisphosphonic acid derivative; C reactive protein; cytochrome P450 1A1; denosumab; farnesyl trans transferase; hydroxymethylglutaryl coenzyme A reductase; omega 3 fatty acid; romosozumab; ubidecarenone; zoledronic acid; Article; bone density; bone mass; bone pain; bone remodeling; bone turnover; cardiovascular disease; cerebrovascular accident; femur fracture; femur intertrochanteric fracture; femur subtrochanteric fracture; fragility fracture; functional magnetic resonance imaging; gene mutation; heart infarction; heart protection; hip fracture; human; inflammation; jaw osteonecrosis; osteolysis; osteoporosis; oxidative stress; patient compliance; spine fracture; whole exome sequencing